Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.17 (market cap $29.97B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33.98. The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FNGU | |
|---|---|---|
Market Cap | $29.97B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $36.15 |
52-Week Low | $205.48 | $13.73 |
Enterprise Value | $27.93B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
FNGU, a 3X leveraged ETN tracking FANG+ stocks, trades at $32.19, down 1.62% on the day. Technical indicators show a bullish trend with moving averages supporting upside, but RSI levels above 70 suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-day loss reported on June 5, 2026 (24/7 Wall Street).
The outlook remains high-risk due to leverage amplifying moves; potential for rapid gains exists if tech rallies, but structural decay and volatility erosion pose severe risks. Investors must understand the product's design, as hidden costs beyond the 0.95% fee can significantly impact returns over time.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
